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Abstract
Background: An increasing number of neo-adjuvant breast cancer studies are being conducted and a novel
model for tumor biological studies, the “window-of-opportunity” model, has revealed several advantages. Change
in tumor cell proliferation, estimated by Ki67-expression in pre-therapeutic core biopsies versus post-therapeutic
surgical samples is often the primary end-point. The aim of the present study was to investigate potential
differences in proliferation scores between core biopsies and surgical samples when patients have not received any
intervening anti-cancer treatment. Also, a lack of consensus concerning Ki67 assessment may raise problems in the
comparison of neo-adjuvant studies. Thus, the secondary aim was to present a novel model for Ki67 assessment.
Methods: Fifty consecutive breast cancer cases with both a core biopsy and a surgical sample available, without
intervening neo-adjuvant therapy, were collected and tumor proliferation (Ki67, MIB1 antibody) was assessed
immunohistochemically. A theoretical model for the assessment of Ki67 was constructed based on sequential
testing of the null hypothesis 20% Ki67-positive cells versus the two-sided alternative more or less than 20%
positive cells..
Results: Assessment of Ki67 in 200 tumor cells showed an absolute average proliferation difference of 3.9%
between core biopsies and surgical samples (p = 0.046, paired t-test) with the core biopsies being the more
proliferative sample type. A corresponding analysis on the log-scale showed the average relative decrease from the
biopsy to the surgical specimen to be 19% (p = 0.063, paired t-test on the log-scale). The difference was significant
when using the more robust Wilcoxon matched-pairs signed-ranks test (p = 0.029). After dichotomization at 20%,
12 of the 50 sample pairs had discrepant proliferation status, 10 showed high Ki67 in the core biopsy compared to
two in the surgical specimen (p = 0.039, McNemar’s test). None of the corresponding results for 1000 tumor cells
were significant - average absolute difference 2.2% and geometric mean of the ratios 0.85 (p = 0.19 and p = 0.18,
respectively, paired t-tests, p = 0.057, Wilcoxon’s test) and an equal number of discordant cases after
dichotomization. Comparing proliferation values for the initial 200 versus the final 800 cancer cells showed
significant absolute differences for both core biopsies and surgical samples 5.3% and 3.2%, respectively (p < 0.0001,
paired t-test).
Conclusions: A significant difference between core biopsy and surgical sample proliferation values was observed
despite no intervening therapy. Future neo-adjuvant breast cancer studies may have to take this into consideration.
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Neo-adjuvant therapy is where a systemic cancer ther-
apy is delivered with a therapeutic intention for a period
of months prior to a local treatment for the primary
tumor such as surgical removal [1-3]. In a pre-operative
setting, where neo-adjuvant therapy is not yet recom-
mended, a novel pharmaceutical can be evaluated in a
so-called “window-of-opportunity” study with the
experimental therapy given between diagnosis and
tumor removal [4-10]. Comparison of the pre-treatment
core biopsy and the post-treatment surgical sample
establishes the efficacy of the experimental therapy often
using change in tumor cell proliferation as a primary
end-point [11-15]. Proliferation is a key feature of tumor
progression and it is widely estimated immunohisto-
chemically using the Ki67 antibody MIB-1. Ki67 is a
nuclear protein of unclear function present in all prolif-
erating cells, both normal and tumor [16,17]. Although
widely used as a predictive marker in neo-adjuvant
breast cancer studies, less is known about Ki67 expres-
sion in an untreated cohort and potential baseline dis-
parity between core biopsies and their corresponding
surgical samples [18,19]. Furthermore, there is a lack of
consensus concerning the optimal number of cancer
cells needed to achieve reliable Ki67 results [7,14,20-23].
The aim of this study was to map possible fundamental
differences in Ki67 expression between core biopsies
and their corresponding surgical samples. The secondary
aim was to present a model for Ki67 assessment, which
has the potential to make results from future neo-adju-
vant studies more comparable.
Materials and methods
A retrospective cohort of fifty consecutive breast cancer
cases from 2008 and 2009, with both core biopsy and
corresponding surgical sample available, were retrieved
from the Department of Pathology, Skåne University
Hospital, Lund, Sweden. No intervening anti-cancer
treatment between the core biopsy sampling and opera-
tion had been given. The study was approved by the
Ethical Committee at Lund University (Dnr 529).
Histopathological analyses
According to common practice at the Department of
Pathology, tumor specimens were formalin-fixed and
representative parts of the breast carcinomas and all
needle core biopsies were paraffin-embedded. Sections
w e r ec u ta t4μm, deparaffinized, and rehydrated in
graded alcohols. Antigen retrieval was performed in a
microwave oven in Citrate buffer pH 6 for 20 min.
Expression of Ki67 was determined using the LSAB+,
Dako REAL™ Detection Systems (K5001, Dako
Glostrup, Denmark). The Ki67 antibody (clone MIB1
DAKO Glostrup, Denmark)w a sd i l u t e d1 : 5 0 0a n d
incubated for 25 min in a TechMate 500 Plus (DAKO)
and visualized with DAB (3,3’-Diaminobenzidine).
Ki67 evaluation
First, eosin and hematoxylin stains were examined on
2× and 10× magnification to identify cancerous regions
within a tissue sample. Second, the MIB-1 stain for Ki67
was examined on 2× and 10× magnification to identify
hotspots, areas with increased numbers of Ki67 positive
cells within the previously identified cancerous regions.
Finally, using 40× magnification over the hotspot, 10
cancer cells at a time were evaluated. Nuclei more
brown than blue were scored positive. The number of
Ki67-positive tumor cells from each set of 10 was
recorded. This procedure was performed 100 times for a
total of 1000 cells. The field of magnification was
divided visually into eight “pie slices” that were evalu-
ated from the outer edge of the field towards the centre.
T h es l i c e sw e r ee v a l u a t e di nac l o c k w i s eo r d e r .W h e n
the entire field of magnification did not include 1000
cancer cells, a new field was chosen, often within the
same hotspot and adjacent to the original field. Occa-
sionally, the chosen hotspot did not contain 1000 cancer
cells. In these cases the magnification was reduced and
a new hotspot was located and evaluated in the manner
described above. In cases with no additional hotspots, a
random field of tumor cells was chosen and evaluated,
until a count of 1000 was reached. In cases where no
initial hotspot could be discerned, the fields were chosen
at random and 1000 cancer cells were evaluated. Each
core biopsy and surgical sample was evaluated twice,
four weeks between evaluations, by a single observer
(QR) with the observer blinded to the relationships
between samples. Surgical samples were counted first in
a random order followed by the core biopsy samples,
also assessed in random order. The observer (QR) is a
medical doctor and a PhD student at the Department of
Oncology/Pathology and has undergone supervised edu-
cation in Ki67 assessment by a senior breast pathologist
(DG).
Statistical analysis and model development
Differences in Ki67 levels between core biopsies and
surgical samples were in a pre-planned manner evalu-
ated for 200 and 1000 tumor cells, based on the number
of tumor cells evaluated in Swedish clinical practice and
the number of tumor cells commonly counted in breast
cancer studies [7,14,20-23]. Ki67 differences with and
without log-transformation of the values, were evaluated
using the paired t-test. Analysis on the original scale
corresponds to comparison of absolute percentages
whereas analysis on the log-scale compares relative per-
centages. The paired t-test was also used to compare
Ki67 levels within sample types, comparing the initial
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Page 2 of 12200 to the final 800 cells counted. Since outliers were
detected, the null hypothesis of equal distributions was
also tested non-parametrically using the Wilcoxon
matched-pairs signed-ranks test. Bland-Altman analysis
was used to assess heteroscedasticity and trends in bias
with increasing Ki67 value. The order of the samples
(Sample ID in Figures 1, 2 and 3) is from lowest to
highest proliferation based on the average over core
biopsy and surgical sample for 200 counted cells.
A dichotomized Ki67 variable was created using 20%
positive cells as cut-off. The McNemar test was used to
evaluate if differences in both directions were equally
likely after dichotomization. The cut-off value of 20%
was chosen based on the present data, classifying one-
third of the samples as positive and two-thirds as nega-
tive, and on previous Swedish studies indicating that a
cut-off near the seventh decile correlates with the high-
est risk of developing metastases [24]. Model develop-
ment commenced by defining a stopping rule for the
number of cells necessary to count in order to reject the
null hypothesis of 20% Ki67-positive cells. The rule was
based on the assumption of a homogeneous Ki67expres-
sion. A sequential test strategy was adopted, which
allows testing of the null hypothesis. Samples are first
evaluated by counting cancer cells in ten cell increments
and recording the number of Ki67-positive cells. Testing
of the null hypothesis begin when 100 cells have been
evaluated. Thereafter testing is done at 10 cell cumula-
tive intervals i.e. 110, 120 and up to 400 counted cancer
cells. An exact two-sided binomial test was used and the
significance level was set to 0.012 for each test. The
rationale behind this nominal p-value is that simulation
studies show that it preserves the overall significance
level of the procedure at approximately 0.05.
All tests were two-sided and the significance level was
set to 0.05. The statistics package Stata 11.1 (StataCorp
LP, College Station, TX, USA, 2010) was used for statis-
tical analysis.
Results
Patient and tumor data
Among the fifty breast cancer cases four women had
previously had breast cancer in the contra-lateral breast
and one woman had recurrent breast cancer in the ipsi-
lateral breast. Mean time interval from core biopsy sam-
pling to surgery was 31 days with a median of 28 days
and a range from 8 to 77 days. Nodal status was
assessed according to AJCC 6
th [25] with one third of
the patients being node positive. Further patient and
tumor characteristics are presented in Table 1.
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Figure 1 Comparison of Ki67 results. Variation in Ki67-determined proliferation values for core-biopsies (left) and surgical samples (right)
between counts 1 and 2 of 200 tumor cells.
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Page 3 of 12Agreement between two repeated Ki67 assessments
Ki67 assessment of each sample pair, core biopsy with
corresponding surgical sample, was performed twice.
T h em e a nd i f f e r e n c eo ft h et w oe v a l u a t i o n so ft h e5 0
core biopsies at 200 cells level was 2.6% and the stan-
dard deviation of the differences 5.7%. The correspond-
ing figures for the surgical samples were 1.8% and 5.6%,
respectively (Figure 1). For both sample types, the aver-
age was significantly higher in the second evaluation (p
= 0.002 for core biopsies and p = 0.02 for surgical sam-
ples) but the general shift of level was not significantly
different for the two sample types (p = 0.44). Prior to
the above described analyses of potential differences
between the two counts the second count was randomly
chosen and used for all statistical analyses.
Ki67 assessment of 200 cancer cells
The first 200 of the 1000 cancer cells evaluated for
Ki67 were analyzed separately based on Swedish clini-
cal practice and the experience of the first 200 tumor
cells counted in the vast majority represent a single
hotspot. Core biopsies showed a mean proliferation
3.9% higher than the surgical samples’ mean prolifera-
tion (95% CI: 0.1-7.8%, p = 0.046, paired t-test), but no
consistent pattern of either the core biopsy or surgical
sample being higher than the other was seen (Figure
2). Sensitivity analysis revealed one pair of samples to
be highly influential. When excluding this sample pair,
with an extreme difference in Ki67, the mean differ-
ence increased to 4.8% (95% CI: 1.2-8.3%, p = 0.009).
This profound effect of a single sample pair on the
results suggested that the assumptions behind the t-
test for the complete set of 50 tumors are question-
able. The null hypothesis of equal distributions was,
however, also rejected when using the non-parametric
Wilcoxon matched-pairs signed-ranks test (p = 0.029).
The median absolute difference between core biopsies
and the corresponding surgical sample was 3.5% with a
range from -38% to +27%. Analysis on the log-scale
showed the Ki67 values from the surgical specimens to
be on average 19% lower (geometric mean of the ratios
= 0.81, 95% CI: 0.65-1.01) compared to the values
from the core biopsies (p = 0.063). Also this estimate
is influenced by extreme values, as can be seen in the
Bland-Altman plots for the two scale alternatives pre-
sented in Figure 3. On the linear scale, the variability
seems to increase with increasing Ki67-level whereas
the opposite pattern is seen on the multiplicative scale.
T h eb i a sd o e sn o ts e e mt ov a r yw i t hi n c r e a s i n gK i 6 7 -
level.
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Figure 2 Differences in proliferation. Proliferation values for core biopsies and surgical samples as determined using the Ki67 bio-marker for
the 200 (left) and 1000 (right) tumor cells evaluated.
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Page 4 of 12Dichotomization of Ki67 into categories of high or low
proliferation using a 20% cut-off value resulted in 12
sample pairs with discrepant Ki67 status. Ten patients
had core biopsies classified as highly proliferative and
their respective surgical samples classified as low prolif-
eration, while two patients showed the opposite pattern
(Table 2). This disparity in classification demonstrated
significant skewing (p = 0.039, McNemar’s test). All sta-
tistical methods employed show core biopsies as consis-
tently and significantly more proliferative than their
corresponding surgical samples despite no intervening
treatment. Table 3 summarizes these results.
Ki67 assessment of 1000 cancer cells
Analysis of 1000 cancer cells evaluated for Ki67 prolifera-
tion showed core biopsies having an absolute mean pro-
liferation value 2.2% higher than the surgical samples (p
= 0.19, paired t-test). Excluding the single outlier pair
increased the mean difference to 3.1% (p = 0.030). The
median difference in proliferation values between core
biopsies and surgical samples was 2.5% with a range from
-44% to +32% - a difference which was not significant (p
= 0.057) when tested non-parametrically using the Wil-
coxon matched-pairs signed-ranks test. The geometric
mean of the Ki67 ratios (surgical sample/core biopsy)
was 0.85 corresponding to an average relative decrease of
15% (p = 0.18, paired t-test on the log-scale).
Dichotomization into categories of high or low using the
20% cut off-value resulted in eight discrepant pairs with
four patients having core biopsies classified as highly prolif-
erative and respective surgical samples classified as low pro-
liferation, and another four patients with the opposite
pattern. The disparity in classification demonstrated no
skewing (p = 1.0, McNemar’s test). None of the statistical
methods employed show a significant difference between
core biopsy and corresponding surgical sample proliferation
values excepting the t-test excluding the outlier (Table 3).
Ki67 evaluation accuracy
Of the 1000 cancer cells evaluated for Ki67 proliferation,
the initial 200 cells were compared with the final 800 in
a broad attempt to visualize a suspected dilution effect
(Figure 4). The mean proliferation value among core
biopsies was 25.5% and 20.2% for the initial 200 and
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Figure 3 Bland-Altman plots for Ki67-positive cells in surgical samples and core biopsies. (3a) The difference in percentage of Ki67-
positive cells between surgical sample and core biopsy versus the corresponding mean for each of the 50 pairs. Two hundred cells were
counted. The dashed line represents the average difference 3.9% and the solid lines a 95% reference interval around this estimate. (3b) The ratio
of the percentage of Ki67-positive cells in the surgical sample to the corresponding percentage in the core biopsy versus the geometrical mean
for each of the 50 pairs. Two hundred cells were counted. The dashed line at 0.81 represents the geometric mean of the ratios (19% lower Ki67
fraction the surgical sample) and the solid lines a 95% reference interval around this estimate.
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Page 5 of 12final 800 tumor cells, respectively, an absolute difference
of 5.3%. The mean proliferation value among surgical
samples was 21.6% and 18.4% for 200 and 800 cells
respectively, an absolute difference of 3.2%. Both differ-
ences were significant according to the paired t-test, p <
0.0001. Figure 5 is illustrative of this dilution effect and
its plausible consequence when a sample’s proliferation
value is near the cut off-value. The dilution effect can
also be seen in Figure 6, where the mean proliferation
estimate over all the 50 samples of each type is plotted
against the number of cells counted.
Theoretical model for Ki67 evaluation
Assuming homogeneity of the sections with regard to
Ki67 staining and a fixed number of n counted cells, it
is straightforward to calculate an exact k%c o n f i d e n c e
interval (CI), based on the binomial distribution, for the
proportion of Ki67-positive cells under the null hypoth-
esis of 20% positivity. An observed proportion outside
this interval means that the null hypothesis can be
rejected at the (100-k)% significance level. We suggest
to test the null hypothesis not only for one n,b u t
sequentially starting with n = 100 and proceeding in
steps of 10 cells until either significance or a maximum
of 400 counted cells. The lower limit was chosen to get
a reasonably stable estimate of the proportion of Ki67-
positive cells and the upper limit for practical reasons
and to avoid excessive dilution effect. Twenty samples
of the 100 included in our series require evaluation of
more than 400 tumor cells to reliably determine Ki67-
status. This combined with an uncertainty as to when
the dilution effect begins to affect results encouraged
the conservative maximum of 400 cells for evaluation.
Extensive simulations under the null hypothesis showed
that k = 98.8 preserves the overall significance of the
sequential test procedure at 5%. The corresponding
rejection regions can be found in Figure 7.
Discussion
Biological tumor markers are used as measures of clini-
cal efficacy when evaluating novel neo-adjuvant thera-
pies., Ki67 is a biological tumor marker that follows
changes in tumor proliferation between pre- and post-
Table 1 Distribution of clinicopathological variables and
immunohistochemical markers
n (%)
Age: median (range) 63 (25-88) years
Primary breast cancer Yes 49 (98)
No* 1 (2)
Tumor size <20 mm 30 (60)
≥20 and <50 mm 16 (32)
≥50 mm 4 (8)
Tumor type Ductal 44 (88)
Lobular 5 (10)
Mucinous 1 (2)
Histological grade 1 16 (32)
2 19 (38)
3 15 (30)
Estrogen receptor status** Positive 45 (90)
Negative 4 (10)
Progesterone receptor status** Positive 37 (74)
Negative 13 (26)
HER2 status*** Normal 32 (64)
Amplified 8 (16)
Unknown 10 (20)
Axillary node Status† Positive 19 (38)
Negative 30 (60)
Unknown 1 (20)
* Four women had contralateral primary tumors and one woman had
recurrent breast cancer in the ipsilateral breast.
** Positive estrogen and progesterone receptor status when ≥ 10%
*** Patients ≥ 70 years of age and surgery before May 2008 did not routinely
receive an HER2 test.
† See reference given in text.
Table 2 Dichotomization of core biopsies and surgical
samples into low and high proliferation as determined
by Ki67 evaluation using a 20% cut-off value
200 cells 1000 cells
Core biopsies
Surgical samples < 20% >20% Total < 20% > 20% Total
< 20% 19 10 29 29 4 33
>20% 2 19 21 4 13 17
Total 21 29 50 33 17 50
Table 3 Summary of statistical analysis for 200 and 1000
cancer cells after evaluation for Ki-67 proliferation
Statistical test 200 cells 1000 cells
Mean
difference
(95% CI)
p Mean
difference
(95% CI)
p
t-test,
linear scale
3.9% *
0.1% - 7.8%
0.046 2.2%*
-1.1% - 5.6%
0.19
t-test, linear scale
excluding outlier
4.8% *
1.2% - 8.3%
0.009 3.1%*
0.03% - 6.0%
0.03
t-test multiplicative
scale
0.81 **
0.65-1.01
0.063 0.85 **
0.67-1.08
0.18
Wilcoxon*** 0.03 0.06
Disparate pairs
(distribution)
p Disparate
pairs
(distribution)
p
Dichotomy
McNemar’s test
12
(10+2)****
0.04 8
(4+4)****
1.0
*Core biopsies’ average proliferation is higher than surgical samples’
** Geometric mean of the ratios (surgical specimens/core biopsies)
*** Wilcoxon matched-pairs signed-ranks test
****Instance of core biopsies as more proliferative + instances of surgical
samples as more proliferative
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Page 6 of 12therapeutical samples, typically core biopsies and surgi-
cal samples [10,26,27]. These, however, vary in both
sample acquisition and post-acquisition treatment while
containing compositional differences possibly affecting
direct comparison [28]. To the best of our knowledge
these potential differences have not previously been fully
addressed [18,19,29,30]. In this study, we observe signifi-
cant average proliferation differences between paired
core biopsies and surgical samples from patients in an
untreated setting. Importantly, the difference represents
Figure 4 The dilution effect. Comparison of Ki67-determined proliferation values of core biopsies (left) and surgical samples (right) from the
initial 200 versus the final 800 tumor cells evaluated.
Figure 5 Single case demonstration of the dilution effect. Cumulative proliferation values for both core biopsy and surgical sample as
determined using the Ki67 bio-marker from a single patient case. Shown here is a cumulative proliferation value near the pre-determined cut
off-value of 20% changing classification of the sample from high- to low proliferative after inclusion of cells outside a hotspot.
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Page 7 of 12Figure 6 The mean dilution effect. For each sample type, the mean percentage of Ki67-positive cells, over the 50 samples, is plotted against
the number of cells counted. The dashed blue line corresponds to core biopsies and the dashed yellow line to surgical specimens. The shaded
areas represent pointwise 95% confidence intervals for the means. The confidence bands are overlapping. Therefore, an intermediate grayscale
was used for the overlapping area. Please, note that the y-scale does not start at 0%.
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Figure 7 A theoretical model for Ki67 evaluation. The shaded area represents the fractions for which the null hypothesis of 20% Ki67-positive
cells could not be rejected when tested sequentially after 100, 110, 120, ..., up to 400 evaluated cells.
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Page 8 of 12an average difference in proliferation with the core biop-
sies demonstrating a higher proliferation index com-
pared to the surgical samples. The pattern is however
inconsistent between individuals with proliferation dif-
ferences in either directions as demonstrated in Figure 2
and 3. This variability needs to be addressed in interpre-
tations of proliferation differences in future clinical stu-
dies. In many cases a decrease in proliferation values
with increasing number of evaluated tumor cells was
observed. This dilution effect, which we believe to affect
core biopsies and surgical samples unequally, could also
play a role in the systematic difference observed. Finally,
the lack of consensus concerning Ki67 assessment may
raise problems in the comparison of neo-adjuvant stu-
dies. We propose a theoretical model for Ki67 assess-
ment which may diminish the reduction of systematic
differences and improve comparison of future neo-adju-
vant studies.
The decision of including fifty tumors in this study
was not based on a statistical rationale or availability of
tumor tissue, rather regarded as a reasonable number of
samples for detailed Ki67 assessments in this prelimin-
ary study.
Initial analysis using the t-test showed a significant
difference between average proliferation values of core
biopsies versus surgical samples for the first 200 cancer
cells counted, but not for the entire 1000 cells. However,
when a single sample pair with an extreme difference in
proliferation was excluded, significant differences were
observed for both 200 and 1000 cancer cells. This pro-
found effect of a single sample pair suggests that the
distributional assumptions of the t-test are not met.
Hence, a non-parametric analysis, using Wilcoxon
matched-pairs signed-ranks test, was carried out for the
entire series of 50 sample pairs. This analysis revealed a
significant difference in Ki67 expression between core
biopsies and surgical samples, but only for the first 200
tumor cells counted. The Ki67-fractions in core biopsies
and surgical samples were also compared on a multipli-
cative scale - i.e. as ratios. This scale should theoretically
be a better choice, compared to the linear, if the varia-
tion in Ki67 increases with increasing average value, but
the drawback is that ratios for low Ki67 values are unre-
liable. The geometrical mean of the ratios (surgical sam-
ple/core biopsy) was 0.81. Thus, the decrease in the
surgical specimen was, on average, 19% relative to the
core biopsy (p = 0.063).
The observed differences in Ki67 expression between
the two types of samples leads to discordances after
dichotomization at 20% and, for 200 cells, positivity in
the core biopsy and negativity in the surgical sample
was significantly more common than the opposite pat-
tern. Random differences between the paired samples
were expected due to the heterogeneity of the samples,
but the significant systematic difference of the first 200
cells was unexpected. A closer examination of the statis-
tical results was undertaken to better penetrate probable
causes.
For clinical use, a dichotomized biomarker value is
often preferred as a decision-making tool in choice of
therapy. A dichotomized proliferation variable was thus
created and tested statistically with results summarized
in Table 2. At first glance, evaluating 1000 cancer cells
results in fewer sample pairs with opposing classifica-
tions while eliminating the systematic difference seen
with 200 cells, however, some cumulative Ki67 curves
( F i g u r e5 )d e m o n s t r a t eas l i g h tb u tv i s i b l ei n v e r s er e l a -
tionship between the number of tumor cells evaluated
and proliferation results, a dilution effect. When a sam-
ple’s proliferation value is near the cut-off value and
cancer cells outside of the initial hotspot are included in
the assessment, researchers run the risk of diluting the
actual proliferation percentage from one categorized as
highly proliferative to one that is falsely classified as low
proliferating. To verify this putative dilution effect, pro-
liferation values based on the initial 200 cells were com-
pared with the proliferation values of the latter 800
cells. Values for the first 200 cells were significantly
higher in both core biopsies and surgical samples
despite the evaluations coming from the same samples.
Following this substantiation of the dilution effect we
postulate sample composition and acquirement as pri-
mary factors which are discussed below.
Ki67 evaluation focused on hotspots. In nearly all
samples the initial area of increased proliferation, or
hot-spot, was exhausted before 1000 cells were evalu-
ated leading to areas of lower proliferation being
included in the final Ki67 result. Core biopsies generally
contain fewer cancer cells than surgical samples. Studies
s u g g e s tc o r eb i o p s i e sa r eo f t e na c q u i r e df r o mn e a rt h e
center of a tumor, although knowledge of which area of
the tumor the needle targets, is difficult to elucidate and
might be regarded as random [31,32]. Hotspots, how-
ever, are often noted to occur near the periphery of a
tumor [20]. Therefore, core biopsies could be expected
to have lower proliferation values; however, core biopsy
s a m p l e sm u s tp a s st h r o u g ht h et u m o rp e r i p h e r yi n
order to reach the tumor center and thus may pass
through a hotspot. Assuming a core biopsy includes a
hotspot and at the same time contains fewer cells than a
surgical sample, the hotspot in the core biopsy would be
less affected by dilution than a surgical sample contain-
ing not only entire hotspots, but large areas of low pro-
liferation. Further explanations for the observed
systematic difference relate to both acquisition and
post-acquisition handling of tissue samples. Acquisition
of core biopsies is a relatively quick process with little
time for ischemic damage to affect the sample. Surgical
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Page 9 of 12samples are, however, routinely exposed to varying peri-
ods of ischemia during tumor removal. This hypoxic
damage could result in apoptosis of surgical sample can-
cer cells and lead to lower proliferation values compared
to core biopsies lacking significant hypoxic damage.
Post-acquisition handling of tissue samples also varies
between core biopsies and surgical samples. Core biop-
sies are immediately fixed in formalin while surgical
samples are often stored on ice for varying lengths of
time before commencing formalin fixation. Cold
ischemic damage could lead to further apoptosis. The
nearly instantaneous acquisition and fixation of the core
biopsies allows not only minimal time for apoptosis, but
little opportunity for degradation of the Ki67 nuclear
protein, whereas the combined ischemic times during
and after surgery give ample opportunity for protein
degradation to occur [11]. Further studies are required
to elucidate the extent to which these factors influence
the observed difference between core biopsies and surgi-
cal samples.
The dilution effect, regardless of cause, might be
important to note in clinical pratice if samples are
dichotomized, as only proliferation values near a chosen
cut-off would be affected by the dilution effect. In a
research context, however, where continuous values are
gathered and analyzed as such, the dilution effect could
be relevant over the majority of samples.
A lack of consensus concerning an appropriate cut-off
value for Ki67 exists within the breast cancer research
community [33-36] and might raise problems in com-
parison of neo-adjuvant studies using change in prolif-
eration as an endpoint. The secondary aim of the
present study was to introduce a theoretical model for
Ki67 assessment which may also minimize the difference
in proliferation observed here between core biopsies and
surgical samples. The initial idea of a simple adjustment
factor was discarded due to large ranges and intra-
patient proliferation differences in both directions (Fig-
ure 2 and 3). Instead, we focused on the development of
a theoretical model both optimizing the number of can-
cer cells evaluated for Ki67 and possibly standardizing
the counting practice.
Currently, a predetermined number of cancer cells are
evaluated without regard to sample heterogeneity and
without a general agreement as to an optimal number.
I ti sg e n e r a l l ya s s u m e dt h a tm o r ec e l l se v a l u a t e ds i g -
nifies more reliable results as attested to by narrower
confidence intervals. The underlying assumption when
constructing a CI for the probability of Ki67-positivity,
however, is that the counted cells constitute a random
sample of cells from a homogenous distribution - an
assumption which is certainly not true for small hot-
spots. We observed a dilution effect that despite nar-
rower CIs provides less accurate Ki67-estimates for
samples with small hotspots (Figures 4, 5 and 6). Opti-
mally, cancer cells from a single hotspot are counted
until the null hypothesis of proliferation rate equal to
the cut-off can be rejected at a pre-defined significance
level. Hotspots, however, vary considerably in size and
composition from sample to sample. A dual problem of
accommodating individual sample heterogeneity while
optimizing counting methods emerges.
In summary, we propose the following counting model
to be tested in future neo-adjuvant studies: Evaluate 100
cells for Ki67 proliferation. If the proportion is far
enough from the cut-off value then no further cells
need to be counted. If the cut-off cannot be excluded,
an additional ten cells are evaluated and the correspond-
ing proportion is compared to the limits in Figure 7.
The evaluation continues in ten cell increments until
either the cut-off is rejected or until a maximum of 400
cells is reached. In the latter case, the sample is desig-
nated unclassifiable.
Conclusions
We find it superfluous, even detrimental, to evaluate
1000 cancer cells for Ki67-based proliferation. The
observed inverse relationship between the number of
tumor cells evaluated and proliferation results, is inter-
preted as a dilution effect. A significant difference
between core biopsy and surgical sample proliferation
values was observed for 200 cancer cells despite no
intervening therapy. We postulate sample acquisition,
post-acquisition treatment and compositional differ-
ences, in addition to the demonstrated dilution effect,
between core biopsies and surgical samples to play
roles. We propose a theoretical model for cell count
optimization that hopefully contributes to a reduction of
systematic differences while standardizing the counting
practice for the comparison of future neo-adjuvant stu-
dies. However, this retrospective study requires further
validation in an independent set of samples. Further-
more, studies focusing on sample handling and Ki67
degradation plus additional refinement of the theoretical
model are of interest.
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